Skip to main content Skip to megamenu (after main content)
Meet us next:   ISSCR UK 2025 – 13 February  ●  ELRIG UK 2025 – 20 March  ●  more on our events calendar

Corporate News

Page (2)

PRESS RELEASE: REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)

08 February 2024

REPROCELL will soon add a third clinical pipeline, TIL therapy for cervical cancer, in addition to Stemchymal for spinocerebellar ataxia, and iPSC-derived neuroglial cells for ALS.

Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu

31 January 2024

REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant.

Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives

15 January 2024

SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to globally distribute the high-quality MSCs and MSC derivatives manufactured by Cellcolabs for research and clinical applications. This agreement also includes exclusive distribution in Japan.

End of 2023 Newsletter

15 December 2023

Discover the latest advancements in stem cell and drug discovery research at REPROCELL. From GMP MSC production to Pharmacology-AI services, explore how REPROCELL is revolutionizing the field. Stay updated with their collaborations and partnerships for precision medicine and clinical capabilities.

REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study

24 October 2023

REPROCELL supports Silo Pharma research success, investigating the effects of SPU-21 Peptide on rheumatoid arthritis in a human synovial tissue study

REPROCELL Announces License Agreement with Gameto for the Advancement of its Program to Improve Assisted Fertility using iPSCs

04 October 2023

Gameto plans to use the iPSC line to advance its program, Fertilo, designed to improve IVF and egg freezing.

Bioserve Biotechnologies Partners with BioMavericks Ltd. to Expand Presence in the UK market

27 September 2023

[Hyderabad, India, 27 September 2023] – Bioserve Biotechnologies (India) Pvt Limited, is teaming up with BioMavericks Ltd., a UK-based company.

Innovation Unleashed: REPROCELL's Q1 Recap and Insights

13 July 2023

REPROCELL had a productive first quarter of 2023-24, launching new services, winning grants, and publishing research. Find out more in our news release.

Vernal Biosciences Announces Partnership With REPROCELL: Exclusive Distributorship in Japan for mRNA and LNP Formulation Services

11 July 2023

Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to provide mRNA services in Japan at scale for research and clinical applications

Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer

28 June 2023

REPROCELL has entered into a joint research agreement with Keio University regarding the transfer of technology to produce Tumor Infiltrating Lymphocytes (TIL).